Key Takeaway: Alaunos has reported new preclinical data on ALN1003, indicating a statistically significant reduction in liver weight after adjusting for body fat percentage in a 48-day DIO mouse study. This finding suggests that the observed reduction in liver weight is not solely attributable to body fat. The results are consistent with earlier data regarding lower liver injury enzymes.
Price reaction · baseline $2.08 (2026-06-26 close) · hit pre-market · clean, no other TCRT news in the window
Adjustment for body fat percentage enhances data reliability.
Findings align with previous data on liver injury enzymes.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
ZIO-101
Phase 1 · Solid Tumors
Full Press Release Details
This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this model Liver-weight findings are directionally consistent with previously disclosed data on lower liver injury enzymes,
Frequently Asked Questions
What does the new ALN1003 data indicate?
The data indicates a statistically significant reduction in liver weight after adjusting for body fat percentage.
How was the liver weight measured?
Liver weight was measured in a 48-day DIO mouse study, adjusted for body fat percentage.
Are the findings consistent with previous data?
Yes, the findings are directionally consistent with earlier data on lower liver injury enzymes.